Evidence map›Paper›PMID 30822171›Full record

ArticleDrug delivery2019

Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases.

Scott K Ferguson, David I Pak, Justin L Hopkins, Julie W Harral, Katherine M Redinius, Zoe Loomis, Kurt R Stenmark, Mark A Borden, Thies Schroeder, David C Irwin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Scott K Fergusona Cardiovascular and Pulmonary Research Laboratory, Department of Medicine , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
David I Paka Cardiovascular and Pulmonary Research Laboratory, Department of Medicine , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
Justin L Hopkinsb Department of Mechanical Engineering , University of Colorado , Boulder , CO , USA.
Julie W Harrala Cardiovascular and Pulmonary Research Laboratory, Department of Medicine , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
Katherine M Rediniusa Cardiovascular and Pulmonary Research Laboratory, Department of Medicine , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
Zoe Loomisa Cardiovascular and Pulmonary Research Laboratory, Department of Medicine , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
Kurt R Stenmarka Cardiovascular and Pulmonary Research Laboratory, Department of Medicine , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
Mark A Bordenb Department of Mechanical Engineering , University of Colorado , Boulder , CO , USA.
Thies Schroederc Department of Biochemistry , Johannes-Gutenberg University , Mainz , Germany.
David C Irwina Cardiovascular and Pulmonary Research Laboratory, Department of Medicine , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
University of Colorado Denver · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Boulder · USJohannes Gutenberg University Mainz · DE

Funding

VRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1M
Translational Pulmonary Vascular Biology ProgramT32HL007171 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Sonia Castro Flores, Tim Lahm · 1985 to 2026
$9.4M
The contribution of free hemoglobin in the progression of pulmonary remodelingR01HL125642 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI IRWIN, DAVID CHARLES · 2015 to 2019
$1.9M
NHLBI NIH HHS P01 HL014985NHLBI NIH HHS R01 HL125642NHLBI NIH HHS T32 HL007171
6 · The paper itself

Abstract

Hypoxic pulmonary vasoconstriction (HPV) is a well-characterized vascular response to low oxygen pressures and is involved in life-threatening conditions such as high-altitude pulmonary edema (HAPE) and pulmonary arterial hypertension (PAH). While the efficacy of oral therapies can be affected by drug metabolism, or dose-limiting systemic toxicity, inhaled treatment via pressured metered dose inhalers (pMDI) may be an effective, nontoxic, practical alternative. We hypothesized that a stable water-in-perfluorooctyl bromide (PFOB) emulsion that provides solubility in common pMDI propellants, engineered for intrapulmonary delivery of pulmonary vasodilators, reverses HPV during acute hypoxia (HX). Male Sprague Dawley rats received two 10-min bouts of HX (13% O

Indexed as

AnimalsAntihypertensive AgentsDrug Delivery SystemsDrug Evaluation, PreclinicalEmulsionsFluorocarbonsHypertension, PulmonaryMalePhenylpropionatesPulmonary CirculationPulmonary EdemaPyridazinesRatsRats, Sprague-DawleyTreatment OutcomeWaterambrisentanAntihypertensive AgentsEmulsionsFluorocarbonsPhenylpropionatesPyridazinesWaterambrisentanendothelinhigh altitude pulmonary edemaperfluorocarbonPulmonary hypertensionpulmonary pressuressodium nitrite

Identifiers

PMID30822171
PMCPMC6407583
OpenAlexW2920046686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.